Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02923349 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study, sponsored by Incyte Biosciences International Sàrl.
- Completed
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT02923349: Completed Phase 1 study, sponsored by Incyte Biosciences International Sàrl.
NCT02923349 is a Phase 1 study that has completed, run by Incyte Biosciences International Sàrl. The registered enrollment target is 87 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02923349, a Phase 1 study, has completed, sponsored by Incyte Biosciences International Sàrl.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety and tolerability and assess preliminary efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.
Primary Outcome
Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment
Interventions
- DRUG INCAGN01949
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2016-10-31 |
| Est. Completion | 2019-03-26 |
| Phase | Phase 1 |
What the finished NCT02923349 record still lists
NCT02923349 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (45% higher).
The record links to 0 conditions, and to 1 intervention - of which INCAGN01949 is the first listed.
NCT02923349 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02923349 about?
NCT02923349 is a clinical study titled "A Phase 1/2, Open-Label, Dose-Escalation, Safety Study of INCAGN01949 in Subjects With Advanced or Metastatic Solid Tumors". The purpose of this study is to determine the safety and tolerability and assess preliminary efficacy of INCAGN01949 in subjects with advanced or metastatic solid tumors.
What is the current status of trial NCT02923349?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2016-10-31. Estimated completion is 2019-03-26.
What interventions are being tested in trial NCT02923349?
The interventions under investigation include: INCAGN01949 (DRUG).
Who is sponsoring clinical trial NCT02923349?
This trial is sponsored by Incyte Biosciences International Sàrl, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02923349's enrollment target sits among peer trials
87 651st of 2000 higher than 1,349 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI